A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults. [clinicaltrials:NCT02326194]

Bio2RDF uri

A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults. [clinicaltrials:NCT02326194]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT02326194

Bio2RDF identifier

NCT02326194

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT02326194

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT02326194

anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]

120

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT02326194 arm group 1ae6ed60c6d667f362b1adeb0857aa38 [clinicaltrials_resource:NCT02326194/arm-group/1ae6ed60c6d667f362b1adeb0857aa38]

NCT02326194 arm group 259082dfa1bb7dcfd4344739781d5e1d [clinicaltrials_resource:NCT02326194/arm-group/259082dfa1bb7dcfd4344739781d5e1d]

NCT02326194 arm group d660afa7a3dd07ce63317ef3155affa8 [clinicaltrials_resource:NCT02326194/arm-group/d660afa7a3dd07ce63317ef3155affa8]

NCT02326194 arm group daa16a2a846f4ef567a604350c79de27 [clinicaltrials_resource:NCT02326194/arm-group/daa16a2a846f4ef567a604350c79de27]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:245b0106e3be1922b847a6799a540c10

brief summary [clinicaltrials_vocabulary:brief-summary]

Since its first outbrea ...... stigational Ad5-EBOV vaccine.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

A Phase I Clinical Trial to Ev ...... (Ad5-EBOV) in Healthy Adults.

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:other outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:other-outcome]

Occurrence of adverse reactions after vaccination. within 7 days after the vaccination [clinicaltrials_resource:3a7c05e32399e08046e7d41ab79730ae]

Occurrence of adverse reactions after vaccination. within 7 days after the vaccination [clinicaltrials_resource:41978dcdd86e2eff238dd2e27b150250]

Occurrence of adverse reactions after vaccination. within 7 days after the vaccination [clinicaltrials_resource:6ac904c3c877c93624949add3ec3b76a]

Occurrence of adverse reactions after vaccination. within 7 days after the vaccination [clinicaltrials_resource:a6a6a08a091330a1cca1ac47ecb67376]

Occurrence of adverse reactions after vaccination. within 7 days after the vaccination [clinicaltrials_resource:ebfe0788e7b4f479b8bbf2fd211f5b64]

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Occurrence of adverse reactions after vaccination. within 7 days after the vaccination [clinicaltrials_resource:3a78b2b4c0a02d425a1a9b1b95bc07a4]

Occurrence of adverse reactions after vaccination. within 7 days after the vaccination [clinicaltrials_resource:7d23e4e578a3c98d811f3411749ec133]

Occurrence of adverse reactions after vaccination. within 7 days after the vaccination [clinicaltrials_resource:d6cc540e95424814609b7c16622b40d1]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Occurrence of adverse reactions after vaccination. within 7 days after the vaccination [clinicaltrials_resource:3abc8c056452e93797118c127cf64eb5]

Occurrence of adverse reactions after vaccination. within 7 days after the vaccination [clinicaltrials_resource:6c9a3bcfe85579d1e50ab0c9a27db283]

Occurrence of adverse reactions after vaccination. within 7 days after the vaccination [clinicaltrials_resource:8007abdc3f7fe6a45f96865ec41072a0]

Occurrence of adverse reactions after vaccination. within 7 days after the vaccination [clinicaltrials_resource:a86d54004c60be7d3dc82f12246a0abb]

Occurrence of adverse reactions after vaccination. within 7 days after the vaccination [clinicaltrials_resource:b670a21d2115925dfb7e7adbc4b80903]

Occurrence of adverse reactions after vaccination. within 7 days after the vaccination [clinicaltrials_resource:d033a6d35098f03f4ad47142563f0f21]

collaborator [clinicaltrials_vocabulary:collaborator]

Jiangsu Province Centers for Disease Control and Prevention [clinicaltrials_resource:b93e7e18b6c9d98b47ccb8617598bfec]

completion date [clinicaltrials_vocabulary:completion-date]

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT02326194 [clinicaltrials_resource:9be60784254e7584d2a3d22b0cc5dbb6]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2014-12-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

placebo (two doses) [clinicaltrials_resource:1a504edca372fc7490da87300f91bf91]

High dose Ebola Zaire vaccine (Ad5-EBOV) [clinicaltrials_resource:3c85b7fb5dae17941f3daf4bf16a0d3d]

placebo (one dose) [clinicaltrials_resource:4c804416fa3dc97553453e4f296316dd]

Low dose Ebola Zaire vaccine (Ad5-EBOV) [clinicaltrials_resource:8cb4d5b3d227ba2a0e191084d29466a6]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

Safety,immunogenicity,Ebola

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-03-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Jiangsu Province Centers for Disease Control and Prevention [clinicaltrials_resource:b93e7e18b6c9d98b47ccb8617598bfec]

location [clinicaltrials_vocabulary:location]

Phase 1 vaccine clinical trial center of Jiangsu Provincial Center for Disease Control and Prevention [clinicaltrials_resource:910af2193a2081fcdbb74d800c193017]

nct id [clinicaltrials_vocabulary:nct-id]

NCT02326194

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Phase 1 Double-blind, Dose-e ...... OV) in Healthy Adults in China

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

JSVCT020

http://www.w3.org/2001/XMLSchema#string

overall status [clinicaltrials_vocabulary:overall-status]

Active, not recruiting [clinicaltrials_resource:a6bc1606956390bcd6a391faced78809]

oversight [clinicaltrials_vocabulary:oversight]

China: Food and Drug Administration [clinicaltrials_resource:0656e9fba8f4744bb2eb0165736c72dd]

phase [clinicaltrials_vocabulary:phase]

Phase 1 [clinicaltrials_resource:ee4650e51426c7487977eeea8e7e6850]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:bd19e4a21bf08c8f7cd7e4cd12864a62]

source [clinicaltrials_vocabulary:source]

Jiangsu Province Centers for Disease Control and Prevention [clinicaltrials_resource:b93e7e18b6c9d98b47ccb8617598bfec]

start date [clinicaltrials_vocabulary:start-date]

2014-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT02326194 study design [clinicaltrials_resource:206a9454674169e48d1ebcb7f6fea141]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT02326194

verification date [clinicaltrials_vocabulary:verification-date]

2015-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT02326194

http://www.w3.org/2001/XMLSchema#string

title

A Phase I Clinical Trial to Ev ...... (Ad5-EBOV) in Healthy Adults.

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

A Phase I Clinical Trial to Ev ...... . [clinicaltrials:NCT02326194]

@en